HC Wainwright reissued their buy rating on shares of IntelGenx Technologies (OTCMKTS:IGXT) in a research note issued to investors on Monday morning, AnalystRatings.com reports. They currently have a $1.00 target price on the stock.
A number of other equities analysts have also recently issued reports on the stock. Maxim Group reiterated a buy rating and issued a $1.50 price target on shares of IntelGenx Technologies in a research note on Friday, August 9th. Zacks Investment Research cut shares of IntelGenx Technologies from a buy rating to a hold rating in a research note on Wednesday, July 24th.
Shares of IntelGenx Technologies stock opened at $0.40 on Monday. The stock has a market cap of $37.41 million, a price-to-earnings ratio of -2.86 and a beta of 1.73. The firm’s 50-day moving average is $0.48 and its 200 day moving average is $0.57. IntelGenx Technologies has a 1 year low of $0.39 and a 1 year high of $1.83. The company has a debt-to-equity ratio of 1.02, a current ratio of 4.08 and a quick ratio of 3.93.
IntelGenx Technologies (OTCMKTS:IGXT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01). The firm had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.90 million. IntelGenx Technologies had a negative return on equity of 175.02% and a negative net margin of 541.77%. On average, equities analysts expect that IntelGenx Technologies will post -0.07 EPS for the current fiscal year.
IntelGenx Technologies Company Profile
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.
Read More: Bid-Ask Spread
Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.